Life‐threatening hypophosphatemia after right hepatic lobectomy for live donor adult liver transplantation

James J. Pomposelli, Elizabeth A. Pomfret, David L. Burns, Ann Lally, Andrea Sorcini, Fredric D. Gordon, W. David Lewis, Roger Jenkins – 30 December 2003 – Life‐threatening hypophosphatemia (phosphorus < 1.0 mg/dL) has been reported only once after liver resection for tumor and was associated with a significant increase in postoperative complications. Hypophosphatemia is associated with reversible cardiac dysfunction, hypoventilation, and impaired immunity.

Transplant legislation: Ethical and practical issues in liver allocation—The case of Switzerland

Zakiyah Kadry, Eberhard L. Renner, Pierre‐Alain Clavien – 30 December 2003 – Ethical and practical issues relating to liver allocation have been discussed in many countries. Several governments, including the United States, have attempted over the past few years to impose new legislation, which has resulted in virulent debates among individual centers, organ procurement agencies, states, and various groups of interest. This report discusses the current ongoing legislative process in Switzerland. In 1999, the people of Switzerland voted to develop transplant legislation.

Disease recurrence after living liver transplantation for primary biliary cirrhosis: A clinical and histological follow‐up study

Etsuko Hashimoto, Masahiko Shimada, Sanshirou Noguchi, Makiko Taniai, Katsutoshi Tokushige, Naoaki Hayashi, Ken Takasaki, Syouhei Fuchinoue, Jurgen Ludwig – 30 December 2003 – We describe the recurrence of primary biliary cirrhosis (PBC) in recipients of living liver transplants. We are not aware of similar previous reports. Because most donors for living liver transplantation (LLT) are blood relatives with close HLA matches, the recurrence of PBC in transplant recipients might offer additional insights in the pathogenesis of the condition.

Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus

James F. Trotter, Michael E. Wachs, Thomas E. Trouillot, Thomas Bak, Marcelo Kugelmas, Igal Kam, Gregory Everson – 30 December 2003 – Since its approval as an immunosuppressive agent in renal transplantation, sirolimus (RAPA) recently has been used in the primary immunosuppression regimen at several liver transplant centers. One of the major side effects of RAPA is hypercholesterolemia, which is reported in up to 44% of patients. We describe our experience in 57 primary liver transplant recipients treated with RAPA and either cyclosporine A (CSA) or tacrolimus (TAC).

Are posttransplantation protocol liver biopsies useful in the long term?

Marina Berenguer, José M. Rayón, Martín Prieto, Victoria Aguilera, David Nicolás, Vicente Ortiz, Domingo Carrasco, Rafael López‐Andujar, José Mir, Joaquín Berenguer – 30 December 2003 – Controversy exists about the usefulness of yearly protocol liver biopsies after liver transplantation, mainly among patients with normal transaminase levels.

Modulation of steady‐state messenger RNA levels in the regenerating rat liver with bile acid feeding

Betsy T. Kren, Cecilia M.P. Rodrigues, Kenneth D.R. Setchell, Clifford J. Steer – 30 December 2003 – Liver regeneration after two thirds partial hepatectomy (PH) is an orchestrated hyperplastic growth process requiring coordinated expression of many genes. The synchronous progression of 95% of the remnant hepatocytes through the cell cycle provides an in vivo model for examining the influence of bile acids on the molecular regulation of hepatocyte replication and growth.

Subscribe to